Breaking AI & Tech News Analyzed

Breakthrough Cancer Drug Reveals Hidden TumorsA smart drug that stops cancer cells "hiding" from treatment can shrink tumours by at least 30% in six of the world's most common forms of the disease, according to early trial results. While immunotherapy treatments have improved survival rates for many patients, their effectiveness can stall or fail when tumour cells hide and then spread.How the Smart Drug WorksResearchers in Oxford have developed a drug designed to stop cancer cells concealing themselves from the immune system, allowing immunotherapy treatments to identify and destroy them. In a trial spanning the UK, France, Spain and Australia, 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers were given the experimental drug, GRWD5769, alongside the immunotherapy treatment cemiplimab.The smart drug was able to remove "invisibility cloaks" from tumour cells, exposing them to the parts of the immune system that attack infections and diseases. This allowed the cemiplimab immunotherapy to pinpoint and destroy the cancer.Trial Results Across Cancer TypesResearchers, led by the Christie NHS foundation trust in Manchester, England, found that tumours shrank in 26 patients. Of those, 15 experienced tumour reductions of at least 30%. All participants had previously failed to respond to treatment, and most had no options left when they joined the study.GRWD5769 was shown to shrink tumours in all six cancer types included in the trial. The drug halted progression of the disease for at least six months in 18% of cervical cancer patients, 32% of liver cancer patients, 36% of bladder cancer patients, 38% of those with neck and head cancer, and more than half of bowel (51%) and lung (55%) cancer patients.Significance for Cancer TreatmentImmunotherapy enlists T-cells – immune system cells that attack infections and diseases – to hunt and destroy cancer. Although it has revolutionised cancer care, it fails in about two-thirds of patients. This is because immunotherapy struggles when tumours hide from the immune system.Tumours can evade the immune system by manipulating an enzyme called ERAP1 (endoplasmic reticulum aminopeptidase 1). By altering this enzyme, cancer cells can hide from a patient's T-cells. GRWD5769 solves this problem by inhibiting ERAP1, which removes cancer's invisibility cloak and makes tumour cells visible to T-cells that could not previously find them.Future Outlook for Cancer TreatmentThe findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago, the world's largest cancer conference. Prof Fiona Thistlethwaite, the principal investigator, noted: "For a drug that is given as a tablet, this is very impressive. It's early days, and we need further studies, but this is a new drug with a new mechanism that clearly helps immunotherapy perform more effectively."The tablets, which were developed by Oxford-based Greywolf Therapeutics and were tolerated well by patients. The trial remains ongoing, with a larger study planned. Cancer Research UK's research information lead, Dr Samuel Godfrey, noted: "Immunotherapy has transformed treatment for some cancers but it doesn't yet work for everyone. This trial seems to show how this new drug could make immunotherapy more effective, including in some cases where immunotherapy had previously failed."

The Voice of a Generation: Kathy Sledge's Musical Journey Passion is the essential ingredient that made Kathy Sledge's musical journey possible, from her early days with Sister Sledge to becoming the voice of iconic songs like "We Are Family." For Sledge, these songs are more than just music—they're statements that brought the world together as a family through song. Lost in Music: The Sister Sledge Experience While "We Are Family" may be the group's most recognized song, Sledge considers "Lost in Music" to be the true theme of Sister Sledge. Having been in the industry since she was 11 years old, Sledge emphasizes the importance of balance to survive the demanding world of music, especially during the early years when the group toured extensively. The Chic Collaboration: Trust and Spontaneity Working with Chic's Nile Rodgers and Bernard Edwards was a defining experience for Sister Sledge. Sledge describes the process as leaning into a director as an actor, built on a foundation of trust. The producers believed in spontaneity, often having Sledge record songs without prior rehearsal to maintain freshness that continues to resonate with audiences today. Disco as Political Resistance Sledge views disco culture as inherently political, pointing to events like the 1979 Disco Demolition in Chicago as examples of industry resistance. She explains how disco challenged music segregation by knocking Neil Diamond and Barbra Streisand's "You Don't Send Me Flowers" from the top spot with Chic's "Le Freak," disrupting industry power dynamics and financial structures. The Myth of Leaving Sister Sledge Addressing one of the biggest untruths written about her, Sledge clarifies that she never left Sister Sledge voluntarily—she was voted out after being offered a solo project with Jimmy Jam and Terry Lewis. Despite wanting to maintain her connection to the group, she was given an ultimatum and prevented from acknowledging her Sister Sledge background, creating significant frustration. Breaking Barriers: Performance Style and Legacy Sister Sledge rarely wore skirts on stage, choosing trousers and jumpsuits for practical movement rather than making a statement. Sledge notes they were among the first girl groups to dance extensively on stage, opening pathways for future groups like Destiny's Child, the Spice Girls, and En Vogue. Their influence continues to shape the performance style of contemporary artists.

The world’s largest randomised trial of a multi‑cancer early detection (MCED) blood test, involving 142,942 NHS participants, did not achieve its main aim of cutting late‑stage cancer diagnoses, according to data presented at the ASCO annual meeting in Chicago.Trial Overview and Primary ObjectiveThe study enrolled adults aged 50‑77 with no cancer symptoms, assigning half to annual Galleri testing alongside standard screening and the other half to standard screening alone. Positive Galleri results triggered diagnostic follow‑up, mirroring the protocol for symptomatic participants in both arms.Key Findings and Statistical OutcomesParticipants: 142,942 screened over three years.Primary endpoint: Combined stage III and IV diagnoses across 12 pre‑specified cancers.Result: No statistically significant reduction in advanced‑stage cancers in the Galleri arm versus control.Secondary signal: Stage IV cancers fell by 14% in the Galleri group, a finding the company Grail highlighted as encouraging.Dr Julie Gralow, ASCO’s chief medical officer, noted the trial showed “some encouraging trends toward tumour downstaging” but emphasized the primary endpoint was not met.Implications for NHS Cancer Screening StrategyExperts such as Prof Richard Houlston (Institute of Cancer Research) warned that the lack of a primary‑endpoint hit undermines any justification for nationwide adoption of Galleri. Prof Peter Johnson, NHS England’s national clinical director for cancer, said the NHS will scrutinise the full data before deciding on future implementation.The trial’s outcome raises questions about the cost‑effectiveness of MCED tests at population scale and may temper enthusiasm for rapid integration into existing screening programmes.Future Directions and Remaining QuestionsMortality outcomes, expected in the next few years, will be critical to assess whether earlier detection translates into survival benefits. Researchers and policymakers will likely await these results before committing to broader rollout, while Grail may refine its assay based on the secondary findings.

The Road to World Cup 2026 Canada's national football team has made significant progress in recent years, with a record of 4W-2L-3D against the United States in their last nine matches. They have also qualified for consecutive World Cups, winning the regional qualifying tournament ahead of Mexico and the USA. Key Player: Alphonso Davies Alphonso Davies, a 25-year-old left back, is Canada's most accomplished player. Born in the Buduburam refugee camp in Ghana, Davies moved to Canada at the age of five and grew up in Edmonton. He captains the Canadian team and has played for Bayern Munich. Accomplished Coach: Jesse Marsch American coach Jesse Marsch, 52, has been hired to lead the team. Marsch has a strong coaching background, having worked in five countries, including Austria, Canada, England, Germany, and the US. He has won titles in two countries and has guided top players like Erling Haaland. Cautionary Tales from Qatar Canada's previous World Cup campaigns in 1986 and 2022 ended with losses in all their games. This time, they face a challenging Group B with Bosnia, Qatar, and Switzerland. To reach the knockout stages, they will need to improve their defense and free up striker Jonathan David to lead the attack. Canada's Group Stage Matches ⚽ June 12: Canada vs Bosnia and Herzegovina (Toronto, Canada), 3pm ET (19:00 GMT) ⚽ June 18: Canada vs Qatar (Vancouver, Canada), 6pm ET (22:00 GMT) ⚽ June 24: Switzerland vs Canada (Vancouver, Canada), 3pm ET (19:00 GMT) Canada's World Cup Squad Goalkeepers: Dayne St Clair (Inter Miami), Maxime Crepeau (Orlando City), Owen Goodman (Crystal Palace) Defenders: Alistair Johnston (Celtic), Derek Cornelius (Marseille), Richie Laryea (Toronto FC), Niko Sigur (Hajduk Split), Joel Waterman (Chicago Fire), Luc de Fougerolles (Fulham), Moise Bombito (Nice), Alphonso Davies (Bayern Munich), Alfie Jones (Middlesbrough) Midfielders: Stephen Eustaquio (Porto), Ismael Kone (Sassuolo), Tajon Buchanan (Villarreal), Mathieu Choiniere (Los Angeles FC), Ali Ahmed (Norwich City), Nathan Saliba (Anderlecht), Liam Millar (Hull City), Marcelo Flores (Tigres UANL), Jacob Shaffelburg (Toronto FC), Jonathan Osorio (Toronto FC) Forwards: Jonathan David (Juventus), Cyle Larin (Southampton), Tani Oluwaseyi (Villarreal), Promise David (Union SG)

The Early Season Surge: Rookies Reshaping the WNBA LandscapeLess than three weeks into the WNBA season, the league has already delivered high-stakes drama, with thirteen games decided by five points or fewer. Amidst this competitive intensity, the spotlight has shifted to the rookie class, who are not only adapting but thriving in the professional spotlight. From elite point guard play to record-breaking shooting performances, the new wave of talent is proving they belong at the highest level.Elite Company: Olivia Miles and the Point Guard BlueprintOlivia Miles has quickly established herself as the premier rookie point guard in the league. Through her first six games, Miles has averaged 15 points and 5 assists, a feat that places her in an exclusive club alongside legends like Candace Parker, Sue Bird, Caitlin Clark, and Sabrina Ionescu. Her ability to see the floor and elevate her teammates is evident, as veteran players like Courtney Williams and Natasha Howard have thrived in their natural roles alongside her. With the Minnesota Lynx sitting in fourth place without their star Napheesa Collier, Miles’ leadership and scoring are crucial to the team's early success.Azzi Fudd's Breakout: Setting the Standard for ShootingAzzi Fudd, the No 1 overall pick, delivered a statement performance against the New York Liberty. In a game that saw intense back-and-forth action, Fudd broke the rookie franchise record for threes with six, finishing with 24 points in 32 minutes off the bench. Her most impressive stat came in the third quarter, where she scored 17 points, the second-most single-quarter points by a rookie in league history. This performance has seemingly cured her early-season shooting struggles, providing a massive confidence boost for the Dallas Wings.Awa Fam and the Seattle Storm's Youth MovementAwa Fam officially joined the Seattle Storm after a successful overseas campaign, including a Spanish league championship. In her debut against the Washington Mystics, Fam scored 10 points, making her the 14th teenager to play in the WNBA and only the second to score double figures in her first game. Her arrival completes a formidable young core for the Storm, alongside Flau'jae Johnson and Dominique Malonga. This depth suggests a bright future for the franchise and the league as a whole.Future Outlook: A Competitive League and Rookie DominanceThe early season data indicates a highly competitive landscape, with the Atlanta Dream currently leading the league at 4-1. The return of Rhyne Howard has bolstered their title hopes, even without All-Star forward Brionna Jones. As the season progresses, the performances of these rookies will likely continue to drive viewership and engagement. With teams like the Indiana Fever and Chicago Sky facing critical matchups, the combination of veteran experience and rookie energy promises to make the remainder of the season one of the most exciting in recent memory.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."

The United States men’s national team has confirmed a 26‑man roster and will face Senegal (Charlotte) and Germany (Chicago) as its last tune‑ups before the 2026 World Cup. With a mid‑cycle coaching change and a star striker in a prolonged scoring slump, the friendlies are a decisive laboratory for Mauricio Pochettino to lock in his starting XI and bench options. USMNT’s Final Warm‑up Schedule and Tactical Uncertainties Pochettino admitted he has a provisional XI in mind but remains open to adjustments after training sessions. The coach is unlikely to field a full‑strength side in both matches, preferring to experiment with formations that could shift between a 3‑2‑5 in possession and a 4‑4‑2 or 5‑3‑2 out of possession. Pulisic’s Goal Drought: Numbers That Matter Since 1 January, Christian Pulisic has taken 38 shots for Milan without scoring. In March friendlies he added 6 more attempts with no goal. He has logged 1,164 consecutive minutes for club and country – roughly 13 full matches – without finding the net. The striker’s dry spell is a focal point; a goal before the tournament could restore confidence and influence his role, potentially moving him from a half‑time substitute back to a starter. Defensive Options: Freeman’s Role and the Wing‑Back Conundrum The squad lists ten defenders, suggesting flexibility between a back‑four and a back‑three with wing‑backs. Alex Freeman emerges as a versatile option, having featured in all eight post‑Gold Cup friendlies and capable of operating as a traditional right‑back or a wide centre‑back in a three‑man defence. Freeman played all but three minutes of the US’s six‑match Gold Cup run. He started three of Villarreal’s final La Liga games at right‑back. His performance will determine whether he backs up Sergiño Dest or competes with Joe Scally for minutes. Bench Firepower: Reyna, Balogun and the Emerging Super‑Sub The expanded roster creates room for impact substitutes. Gio Reyna is the most obvious candidate, despite limited club minutes (520 Bundesliga minutes across 19 games for Borussia Mönchengladbach). His last season with over 625 league minutes was 2020‑21. Striker depth includes Folarin Balogun, who offers quick‑turn‑and‑shoot ability, and the contrasting styles of Ricardo Pepi (13 goals in 35 caps) and Haji Wright (7 goals in 20 caps). Both could earn bench minutes as tactical switches in the latter stages of matches. What the Friendlies Reveal About USMNT’s World Cup Prospects If Pulisic breaks his drought against Senegal, he may retain a starting spot, allowing Pochettino to rotate other attackers. Conversely, a strong showing from Reyna or Balogun could cement a super‑sub role that changes the team’s late‑game dynamics. Defensive clarity—whether the US adopts a three‑centre‑back system with wing‑backs or sticks to a traditional back‑four—will hinge on Freeman’s performances and Dest’s fitness. The outcomes of these two matches will shape the tactical blueprint for the group‑stage opener against Paraguay on 12 June.

Lead: Sleep Deprivation Emerges as a Possible Driver of Early-Onset CancerResearch presented at the American Society of Clinical Oncology’s annual meeting in Chicago suggests that irregular sleeping patterns could be a significant, yet modifiable, risk factor for cancers diagnosed before age 50.The Study Linking Sleep Disruption to Early-Onset CancerTwo investigations led by MD Anderson Cancer Center analysed health records of over 18 million U.S. adults aged 18‑50. Participants with chronic insomnia showed a markedly higher incidence of bowel, breast, uterine, and ovarian cancers compared with well‑rested peers.Key Numbers Highlight the Scale of the IssueGlobal early‑onset cancer cases rose from 1.82 million (1990) to 3.26 million (2019), an 80% increase in three decades.Cancer deaths among people in their 30s, 40s, or younger climbed 27% over the same period.In the MD Anderson cohorts, insomnia was associated with up to three‑fold higher cancer risk within five years.Why This Matters for Public Health and Clinical PracticeThe data position sleep quality alongside genetics and lifestyle as a potential lever for curbing the surge in early‑onset cancers. Experts caution that the studies show association, not causation, but note that sleep deprivation can impair immune function and promote behaviours (smoking, poor diet, reduced exercise) that are already linked to cancer.Looking Ahead: Research, Screening, and Prevention StrategiesStakeholders anticipate a wave of longitudinal studies to test whether improving sleep can lower cancer incidence. In the meantime, clinicians are likely to incorporate sleep assessments into risk‑stratification tools, while public‑health campaigns may emphasise sleep hygiene alongside anti‑smoking and sun‑safety messages.

Live Announcement from Manhattan Sets the StageOn Tuesday afternoon, Mauricio Pochettino revealed the United States’ 26‑man squad for the 2026 World Cup during a live broadcast from Pier 17 in Manhattan. The roster mirrors the Guardian’s exclusive leak from the previous Saturday, confirming the final selections ahead of the tournament.Roster Composition: Experience, Age, and Club Distribution13 players with prior World Cup experience13 debutants making their first tournament appearancePlayers drawn from 16 different leagues across 12 countriesThe squad includes the core from the 2022 Qatar campaign: Christian Pulisic, Weston McKennie, Tyler Adams, Chris Richards and Tim WeahSurprise Omissions and Their Tactical ImplicationsThe most striking exclusion is Diego Luna (Real Salt Lake), who logged the second‑most attacking minutes under Pochettino. Central midfielders Tanner Tessmann and Aidan Morris were also left out, raising questions about depth in the midfield engine room. In contrast, Alejandro Zendejas (Club América) earned a spot despite only 139 minutes of playing time during the coach’s tenure, suggesting a strategic gamble on his upside.What the Squad Means for US Prospects at the 2026 World CupPochettino expressed confidence, stating the group is “the best” to achieve success. The team will train at the new National Training Center in Fayetteville, Georgia, before warm‑up friendlies against Senegal (31 May, Charlotte) and Germany (6 June, Chicago). The United States open the tournament on 12 June against Paraguay in Inglewood, followed by matches versus Australia (19 June, Seattle) and Turkey (25 June, Inglewood). The blend of seasoned internationals and fresh talent will be tested against a competitive Group C, and the early schedule offers both challenges and opportunities for the newcomers to make an impact.